Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective

BACKGROUND: Ovarian cancer (OC) is the fifth leading cause of cancer death in women and has the highest mortality rate of gynecological cancers. Niraparib was recently approved by the FDA for the maintenance treatment of adult patients with advanced epithelial OC in complete or partial response to f...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jinan, Hawkes, Carol, Walder, Lydia, Spalding, Chloe, Travers, Karin, Maiese, Eric M, Hurteau, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391297/
https://www.ncbi.nlm.nih.gov/pubmed/34595950
http://dx.doi.org/10.18553/jmcp.2021.27.10.1377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391297/
https://www.ncbi.nlm.nih.gov/pubmed/34595950
http://dx.doi.org/10.18553/jmcp.2021.27.10.1377

Ejemplares similares